FR2432869A1 - Calcitonin and phosphorus association for osteoporosis treatment - pref. also contg. magnesium - Google Patents

Calcitonin and phosphorus association for osteoporosis treatment - pref. also contg. magnesium

Info

Publication number
FR2432869A1
FR2432869A1 FR7823315A FR7823315A FR2432869A1 FR 2432869 A1 FR2432869 A1 FR 2432869A1 FR 7823315 A FR7823315 A FR 7823315A FR 7823315 A FR7823315 A FR 7823315A FR 2432869 A1 FR2432869 A1 FR 2432869A1
Authority
FR
France
Prior art keywords
phosphorus
magnesium
pref
calcitonin
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR7823315A
Other languages
French (fr)
Inventor
Francine Caulin
Charles Alfred Dufoort
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ARMOUR MONTAGU LABORATOIRE
Original Assignee
ARMOUR MONTAGU LABORATOIRE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ARMOUR MONTAGU LABORATOIRE filed Critical ARMOUR MONTAGU LABORATOIRE
Priority to FR7823315A priority Critical patent/FR2432869A1/en
Publication of FR2432869A1 publication Critical patent/FR2432869A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compsns. for the treatment of osteoporosis contain an association of calcination and phosphorus (e.g. inorganic phosphate such as sodium or mono-magnesium phosphate or glycine phosphate) and pref also contain magnesium. Pref. compsns. contain 1500-3000 Medical Research Council (MRC) units of calcitonin associated with 180-360 g of phosphorus (as element) and 18-36 g of magnesium. The effects of calcitonin and phosphorus cpds. on bone formation has been studied, the present invention shows that together they exert a synergistic effect. Admin. of calcitonin in short treatments (sequential treatment) diminishes osteoclastic activity and the duration of the inversion phase, stimulates osteoblastic activity and avoids the troubles of prolonged treatment (reduction of formation of Basic Multicellular Units (BMU)). Pref. 30-70 MRC units per day are injected for 5 days in each 3 week period, whilst 1-2 g of phosphorus (as element) and opt. 0.1-0.2 g of magnesium (as element) are administered each day (continuously), The phosphorus and opt. magnesium are usually administered orally. A usual treatment course is for a period of 4-8 months.
FR7823315A 1978-08-08 1978-08-08 Calcitonin and phosphorus association for osteoporosis treatment - pref. also contg. magnesium Withdrawn FR2432869A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7823315A FR2432869A1 (en) 1978-08-08 1978-08-08 Calcitonin and phosphorus association for osteoporosis treatment - pref. also contg. magnesium

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7823315A FR2432869A1 (en) 1978-08-08 1978-08-08 Calcitonin and phosphorus association for osteoporosis treatment - pref. also contg. magnesium

Publications (1)

Publication Number Publication Date
FR2432869A1 true FR2432869A1 (en) 1980-03-07

Family

ID=9211676

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7823315A Withdrawn FR2432869A1 (en) 1978-08-08 1978-08-08 Calcitonin and phosphorus association for osteoporosis treatment - pref. also contg. magnesium

Country Status (1)

Country Link
FR (1) FR2432869A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004402A1 (en) * 1988-10-21 1990-05-03 The Regents Of The University Of California Treatment of osteoporosis
US5171583A (en) * 1988-10-21 1992-12-15 The Regents Of The University Of California Treatment of osteoporosis using potassium bicarbonate
US5932252A (en) * 1988-10-21 1999-08-03 The Regents Of The University Of California Method and composition for treatment of osteoporosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2333515A1 (en) * 1975-12-01 1977-07-01 Henkel & Cie Gmbh PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CALCIUM METABOLISM DISORDERS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2333515A1 (en) * 1975-12-01 1977-07-01 Henkel & Cie Gmbh PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CALCIUM METABOLISM DISORDERS

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004402A1 (en) * 1988-10-21 1990-05-03 The Regents Of The University Of California Treatment of osteoporosis
US5171583A (en) * 1988-10-21 1992-12-15 The Regents Of The University Of California Treatment of osteoporosis using potassium bicarbonate
US5932252A (en) * 1988-10-21 1999-08-03 The Regents Of The University Of California Method and composition for treatment of osteoporosis
US6027737A (en) * 1988-10-21 2000-02-22 The Regents Of The University Of California Treatment for osteoporosis using potassium salts

Similar Documents

Publication Publication Date Title
RU92004521A (en) APPLICATION OF BISPHOSPHONATES AND EXTRACT OF PARASITIC Glands FOR THE TREATMENT OF OSTEOPOROSIS AND A KIT FOR TREATMENT
ATE179329T1 (en) MEDICINAL PRODUCTS FOR THE TREATMENT OF ARTHRITIS THAT CONTAIN PHOSPHONATES AND NSAIDS
MD1558G2 (en) Method of prophylaxis of mammal acute renal insufficieny utilizing IGF-I insulinlike growth factor
CA2116559A1 (en) Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
DE3852877D1 (en) Pharmaceutical preparations for the prevention of drug tolerance.
CA2124792A1 (en) Methods for the Treatment of Osteoporosis Using Bisphosphonates and Parathyroid Hormone
IL100585A (en) Use of human igf-i in the preparation of anti- cardiac disorder medicaments
ATE112684T1 (en) USE OF IGF-II TO TREAT BONE DISEASES.
ATE183923T1 (en) ENTERAL PREPARATIONS FOR CANCER THERAPY
DE69316013T2 (en) USE OF PHOSPHINATE FOR TREATING OSTEOPOROSIS
ATE193651T1 (en) THERAPEUTIC SYSTEM FOR THE TREATMENT OF PSORIASIS
FR2432869A1 (en) Calcitonin and phosphorus association for osteoporosis treatment - pref. also contg. magnesium
WO1990001321A3 (en) Method for treating and preventing loss of bone mass
KR100271087B1 (en) Protein synthesis stimulator comprising tcf-2 for the treatment of hypoproteinemia
GB2162748B (en) Medicinal composition for the treatment or prevention of acne by oral administration
EG17992A (en) Preparation of a medicament for arthritis and theumatism
NO972558L (en) Set for osteoporosis treatment cycle
ATE87482T1 (en) PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF CEREBRAL PSYCHO-ORGANIC SYNDROMES.
RU2076726C1 (en) Method of psoriasis treatment
NO945059L (en) Preparations for the treatment of arthritis containing phosphonates and NSAIDs
TW224943B (en) The pharmaceutical composition for the stimulation of bone formation
NO945058L (en) Use of phosphonates for the treatment of osteoporosis
FR2244538A1 (en) Reduction of urea levels in blood - by oral administration of powdered bones (otolithe sagita) of fish esp whiting
MX9203784A (en) COMPOSITIONS FOR THE TREATMENT OF OSTEOPOROSIS IN HUMAN BEINGS.

Legal Events

Date Code Title Description
ST Notification of lapse